Patents Represented by Attorney Grant E. Reed
-
Patent number: 7217700Abstract: Dendritic cells play a critical role in antigen-specific immune responses. Materials and methods are provided for treating disease states, including cancer and autoimmune disease, by facilitating or inhibiting the migration or activation of antigen-presenting dendritic cells. In particular, chemokines are used to initiate, amplify or modulate an immune response. In one embodiment, chemokines are used to attract dentritic cells to the site of antigen delivery. An increase number of dendritic at the site of antigen delivery means more antigen uptake and a modified immune response.Type: GrantFiled: January 24, 2001Date of Patent: May 15, 2007Assignee: Schering CorporationInventors: Alain P. Vicari, Christophe Caux
-
Patent number: 7179467Abstract: Nucleic acids encoding various lymphocyte cell proteins from mammalian, including primate, reagents related thereto, including specific antibodies, and purified proteins are described. Methods of using said reagents and related diagnostic kits are also provided.Type: GrantFiled: September 20, 2005Date of Patent: February 20, 2007Assignee: Schering CorporationInventors: Jenny Valladeau, Odile Ravel, Elizabeth Esther Mary Bates, John Ford, Sem Saeland, Serge J. E. Lebecque
-
Patent number: 7166705Abstract: The present invention provides an isolated mammalian histamine receptor, isolated or recombinant nucleic acids and recombinant vectors encoding the same, host cells comprising the nucleic acids and vectors, and methods of making the receptor using the host cells. This invention further provides antibodies and antigen binding fragments thereof which specifically bind to the receptor and are useful for treating medical conditions caused or mediated by histamine. Also provided are screening methods for identifying specific agonists and antagonists of the mammalian histamine receptor.Type: GrantFiled: July 8, 2003Date of Patent: January 23, 2007Assignee: Schering CorporationInventors: Jiang X. Behan, Joseph A. Hedrick, Thomas M. Laz, Frederick J. Monsma, Kelley L. Morse, Shelby P. Umland, Suke Wang
-
Patent number: 7157244Abstract: The present invention provides an isolated mammalian adenosine receptor, isolated or recombinant nucleic acids and recombinant vectors encoding the same, host cells comprising the nucleic acids and vectors, and methods of making the receptor using the host cells. This invention further provides antibodies and antigen binding fragments thereof which specifically bind to the receptor and are useful for treating medical conditions caused or mediated by adenosine. Also provided are screening methods for identifying specific agonists and antagonists of the mammalian adenosine receptor.Type: GrantFiled: January 17, 2001Date of Patent: January 2, 2007Assignee: Schering CorporationInventors: Joseph A. Hedrick, Jean E. Lachowicz, Wei Wang, Eric L. Gustafson
-
Patent number: 7141653Abstract: The present invention relates to antibodies and antigen-binding portions thereof that specifically bind to interleukin 5 (IL-5), which is preferably human IL-5. The invention also relates to human anti-IL-5 antibodies, including chimeric, bispecific, derivatized, single chain antibodies or portions of fusion proteins. The invention also relates to isolated heavy and light chain immunoglobulin molecules derived from anti-IL-5 antibodies and nucleic acid molecules encoding such molecules. The present invention also relates to methods of making anti-IL-5 antibodies, pharmaceutical compositions comprising these antibodies and methods of using the antibodies and compositions thereof for diagnosis and treatment. The invention also provides gene therapy methods using nucleic acid molecules encoding the heavy and/or light immunoglobulin molecules that comprise the human anti-IL-5 antibodies.Type: GrantFiled: March 27, 2003Date of Patent: November 28, 2006Assignees: Schering Corporation, Abgenix, Inc.Inventors: Scott Greenfeder, Jose Corvalan
-
Patent number: 6906028Abstract: The present invention provides a monomeric insulin analog formulation stabilized against aggregation in which the buffering agent is either TRIS or arginine. The stable formulations of the present invention are useful for treating diabetes, and are particularly advantageous in treatment regimes requiring lengthy chemical and physical stability, such as, in continuous infusion systems.Type: GrantFiled: October 3, 2002Date of Patent: June 14, 2005Assignee: Eli Lilly and CompanyInventors: Michael Rosario DeFelippis, Michael Allen Dobbins, Bruce Hill Frank, Shun Li, Dawn Marie Rebhun
-
Patent number: 6551992Abstract: The present invention provides a monomeric insulin analog formulation stabilized against aggregation in which the buffering agent is either TRIS or arginine. The stable formulations of the present invention are useful for treating diabetes, and are particularly advantageous in treatment regimes requiring lengthy chemical and physical stability, such as, in continuous infusion systems.Type: GrantFiled: November 29, 1999Date of Patent: April 22, 2003Assignee: Eli Lilly and CompanyInventors: Michael Rosario DeFelippis, Michael Allen Dobbins, Bruce Hill Frank, Shun Li, Dawn Marie Rebhun
-
Patent number: 6531448Abstract: The present invention relates to insoluble compositions comprising a protein selected from the group consisting of insulin, insulin analogs, and proinsulins; a derivatized protein selected from the group consisting of derivatized insulin, derivatized insulin analog, and derivatized proinsulin; a complexing compound; a hexamer-stabilizing compound; and a divalent metal cation. Formulations of the insoluble composition are suitable for both parenteral and non-parenteral delivery for treating hyperglycemia and diabetes. Microcrystal forms of the insoluble precipitate are pharmaceutically analogous to the neutral protamine Hagedorn (NPH) insulin crystal form. Surprisingly, it has been discovered that suspension formulations of such insoluble compositions possess unique and controllable dissolution properties that provide therapeutically advantageous glucodynamics compared with insulin NPH formulations.Type: GrantFiled: December 21, 1998Date of Patent: March 11, 2003Assignee: Eli Lilly and CompanyInventor: Mark Laurence Brader
-
Patent number: 6465426Abstract: The present invention relates to insoluble compositions containing acylated proteins selected from the group consisting of acylated insulin, acylated insulin analog, and acylated proinsulin, and formulations thereof. The formulations are suitable for parenteral delivery or other means of delivery, to a patient for extended control of blood glucose levels. More particularly, the present invention relates to compositions comprised of an acylated protein complexed with zinc, protamine, and a phenolic compound such that the resulting microcrystal is analogous to the neutral protamine Hagedorn (NPH) insulin crystal form. Surprisingly, it has been discovered that compositions of such acylated proteins have therapeutically superior subcutaneous release pharmacokinetics, and more extended and flatter glucodynamics, than presently available commercial preparations of NPH insulin.Type: GrantFiled: January 17, 2001Date of Patent: October 15, 2002Assignee: Eli Lilly and CompanyInventor: Mark Laurence Brader
-
Patent number: 6444641Abstract: Fatty acid-acylated insulin analogs are soluble at moderately acidic pH and provide long-acting basal control of glucose levels. In such a molecule, the insulin analog portion comprises an insulin A-chain, or an analog thereof, properly cross-linked to an analog of the insulin B-chain, wherein the &egr;-amino group of a Lys residue at either positions 28 or 29 of the B-chain analog is acylated with a fatty acid. The insulin analog portion of the molecules comprises an A-chain of insulin, or an analog thereof, with an optional Arg at position 0, properly cross-linked to a B-chain analog that includes Arg at positions 31 and 32.Type: GrantFiled: July 7, 2000Date of Patent: September 3, 2002Assignee: Eli Lilly CompanyInventor: David Benjamin Flora
-
Patent number: RE37971Abstract: The present invention relates to the acylation of proteins. More particularly, the invention relates to a one-step process for selectively acylating the free &egr;-amino group of insulin, insulin analog, or proinsulin in the presence of a free &agr;-amino group.Type: GrantFiled: July 8, 1999Date of Patent: January 28, 2003Assignee: Eli Lilly and CompanyInventors: Jeffrey C. Baker, Victor J. Chen, Jose M. Hanquier, Aidas Kriauciunas, Brian A. Moser, Robert T. Shuman